Preoperative chemoradiation with raltitrexed (Tomudex) in T2/N+ and T3/N+ rectal cancers: a phase I study.

Vincenzo Valentini, Carlo Ratto, Giovanni Doglietto, Alessio Giuseppe Morganti, Daniela Smaniotto

Risultato della ricerca: Contributo in rivistaArticolo in rivista

22 Citazioni (Scopus)

Abstract

Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study. Valentini V1, Doglietto GB, Morganti AG, Turriziani A, Smaniotto D, De Santis M, Ratto C, Sofo L, Cellini N. Author information Abstract The use of raltitrexed ('Tomudex') as concomitant chemotherapy during preoperative radiotherapy in chemonaïve patients with stage II/III rectal cancer has been examined in this study and its recommended dose in conjunction with radiotherapy investigated. Forty-five Gray (Gy) of radiotherapy (1.8 Gy daily, 5 days per week) was delivered to the posterior pelvis, followed by a 5.4 Gy boost. Single doses of raltitrexed (2.0, 2.5 and 3.0 mg/m(2)) were administered on days 1, 19 and 38. Only 1 of the 15 patients entered experienced a dose limiting toxicity (DLT) (grade 3 leucopenia) at the 3.0 mg/m(2) dose level. The overall response rate was 80% (five complete responses, seven partial responses). These preliminary data suggest that raltitrexed is a well tolerated and effective treatment when combined with preoperative radiotherapy in patients with stage II/III rectal cancer. The recommended dose of raltitrexed for future phase II studies will be 3.0 mg/m(2). PMID: 11597383 [PubMed - indexed for MEDLINE]
Lingua originaleEnglish
pagine (da-a)2050-2055
Numero di pagine6
RivistaEuropean Journal of Cancer
Stato di pubblicazionePubblicato - 2001

Keywords

  • rectal cancer

Fingerprint

Entra nei temi di ricerca di 'Preoperative chemoradiation with raltitrexed (Tomudex) in T2/N+ and T3/N+ rectal cancers: a phase I study.'. Insieme formano una fingerprint unica.

Cita questo